ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
Top Page
ASKA Pharmaceutical Holdings Co., Ltd.
(4886)
Select Model
Select Model
Rating:76Outperform
Price Target:
¥3,089.00
▲(51.57% Upside)
Action:UpgradedDate:02/03/26
The score is driven mainly by solid financial fundamentals (growth and a stronger balance sheet), partially tempered by weaker 2025 profitability and cash-flow consistency. Technicals add support with a clear uptrend and positive momentum, while valuation is reasonable with a modest dividend yield.
Positive Factors
Revenue Growth
Sustained multi-year top-line growth demonstrates durable product demand and expanding commercial traction in core therapeutic areas. This underlying revenue momentum supports longer-term investment in R&D and lifecycle management, reducing reliance on one-time gains and improving predictability of future cash generation.
Negative Factors
Profitability Compression
A meaningful one-year decline in net margin signals rising operating expenses, pricing pressure, or increased SG&A/R&D burden that could persist. Lower net profitability reduces retained earnings for reinvestment and weakens resilience to cost inflation or competitive pricing over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi-year top-line growth demonstrates durable product demand and expanding commercial traction in core therapeutic areas. This underlying revenue momentum supports longer-term investment in R&D and lifecycle management, reducing reliance on one-time gains and improving predictability of future cash generation.
Read all positive factors
ASKA Pharmaceutical Holdings Co., Ltd. (4886) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥72.76B
Dividend Yield2.52%
Average Volume (3M)49.10K
Price to Earnings (P/E)8.6
Beta (1Y)0.56
Revenue Growth5.44%
EPS Growth-20.33%
CountryJP
Employees762
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)59.10
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.00
Price to Sales (P/S)1.02
P/FCF Ratio-137.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)¥71.06B
ASKA Pharmaceutical Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the area...
How the Company Makes Money
ASKA Pharmaceutical Holdings generates earnings primarily through the consolidated business performance of its pharmaceutical subsidiaries. The main revenue stream is sales of prescription pharmaceuticals to healthcare channels (e.g., wholesalers/...
ASKA Pharmaceutical Holdings Co., Ltd. Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
78
Positive
Cash Flow
75
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.43B | 64.14B | 62.84B | 60.46B | 56.61B | 55.18B |
| Gross Profit | 31.79B | 31.34B | 30.66B | 28.59B | 26.35B | 25.38B |
| EBITDA | 7.39B | 7.58B | 9.16B | 8.24B | 7.68B | 6.97B |
| Net Income | 5.07B | 5.10B | 7.54B | 4.24B | 4.29B | 2.71B |
Balance Sheet | ||||||
| Total Assets | 102.95B | 103.25B | 93.31B | 87.14B | 83.30B | 82.58B |
| Cash, Cash Equivalents and Short-Term Investments | 7.23B | 11.16B | 17.24B | 17.91B | 17.10B | 10.51B |
| Total Debt | 13.77B | 10.90B | 9.48B | 12.62B | 14.05B | 16.39B |
| Total Liabilities | 33.72B | 34.06B | 31.38B | 32.60B | 34.40B | 38.07B |
| Stockholders Equity | 65.44B | 65.31B | 61.93B | 54.53B | 48.89B | 44.51B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -475.00M | 166.00M | 2.89B | 2.26B | 5.51B |
| Operating Cash Flow | 0.00 | 2.48B | 1.49B | 3.35B | 2.84B | 6.54B |
| Investing Cash Flow | 0.00 | -6.12B | 1.71B | -1.13B | 6.74B | -2.87B |
| Financing Cash Flow | 0.00 | -2.96B | -3.94B | -1.82B | -3.00B | -455.00M |
ASKA Pharmaceutical Holdings Co., Ltd. Technical Analysis
Positive
2038.00
Price Trends
2380.26
Positive
2204.02
Positive
2248.32
Positive
Market Momentum
118.09
Negative
73.22
Negative
90.19
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4886, the sentiment is Positive. The current price of 2038 is below the 20-day moving average (MA) of 2410.80, below the 50-day MA of 2380.26, and below the 200-day MA of 2248.32, indicating a bullish trend. The MACD of 118.09 indicates Negative momentum. The RSI at 73.22 is Negative, neither overbought nor oversold. The STOCH value of 90.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4886.
ASKA Pharmaceutical Holdings Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥149.30B | 93.62 | -2.58% | 4.16% | -5.99% | -96.04% | |
76 Outperform | ¥72.76B | 8.62 | ― | 2.52% | 5.44% | -20.33% | |
73 Outperform | ¥118.25B | 12.60 | 4.81% | 2.34% | 4.35% | 48.30% | |
69 Neutral | ¥87.22B | 8.41 | ― | 3.36% | 11.65% | 93.46% | |
68 Neutral | ¥63.21B | 35.63 | 5.01% | 2.39% | 12.01% | -51.38% | |
63 Neutral | ¥42.19B | 10.42 | ― | 2.75% | 7.56% | -48.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,734.00
489.04
21.78%
JP:4521
Kaken Pharmaceutical Co
4,145.00
351.53
9.27%
JP:4554
Fuji Pharma Co., Ltd.
2,464.00
1,201.57
95.18%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,475.00
587.46
20.34%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,657.00
280.65
20.39%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,402.00
357.80
34.27%
ASKA Pharmaceutical Holdings Co., Ltd. Corporate Events
ASKA sets 2035 long-term vision and unveils 2028 medium-term growth plan
Mar 23, 2026
ASKA Pharmaceutical Holdings has unveiled a long-term management blueprint dubbed ASKA VISION 2035, setting a 10-year ambition to achieve sustainable growth while enhancing its contribution to society through purpose-driven business execution. The...
ASKA Pharma Launches Restricted Stock Plan for Employee Shareholders
Mar 2, 2026
ASKA Pharmaceutical Holdings has approved the introduction of a restricted stock incentive plan for members of its Employee Stock Ownership Association across the group, excluding corporate officers. The scheme will allow eligible employees to acq...
ASKA Pharmaceutical to Adopt Audit Committee Structure and Streamline Governance
Mar 2, 2026
ASKA Pharmaceutical Holdings will shift to a company structure with an audit committee, pending shareholder approval at its June 24, 2026 general meeting. The new framework will place a majority of outside directors on the audit committee to stren...
ASKA Pharma Hits Record Sales but Profit Slips on Higher R&D and Overseas Costs
Feb 2, 2026
ASKA Pharmaceutical Holdings reported consolidated net sales of 54.4 billion yen for the third quarter of FY2025, a 9.1% year-on-year increase and a record-high level, driven by steady domestic performance and growing contributions from its overse...
ASKA Pharmaceutical Boosts Sales but Sees Profit Decline, Keeps FY2025 Outlook Intact
Feb 2, 2026
ASKA Pharmaceutical Holdings reported consolidated net sales of ¥54.5 billion for the nine months ended December 31, 2025, up 9.1% year on year, but operating profit fell 10.6% to ¥4.9 billion and profit attributable to owners of parent ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.